RxDoctor Payments Data

Joseph Mularczyk, MD

Cardiovascular Disease · Evergreen Park, ILNPI 1215950720

Payments from drug & device makers

$968in general payments, 2019–2025

Across 49 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$425
  • Novartis$231
  • Abbott$126
  • Johnson & Johnson$49
  • AstraZeneca$48
  • Edwards Lifesciences$32
  • plus $57 from 4 others

What the payments were for

  • Food & beverage$968100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$968 in reported general payments places this provider in the 35th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$148,487
Medicare patients
2,228
Services billed
3,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$85,959
EntrestoSacubitril/Valsartan45$72,961
JardianceEmpagliflozin34$57,209
Repatha SureclickEvolocumab22$24,104
FarxigaDapagliflozin Propanediol12$19,812
XareltoRivaroxaban11$17,862
Atorvastatin Calcium263$2,925
Metoprolol Succinate135$2,079
Ezetimibe64$1,579
Nifedipine ErNifedipine32$1,560
LopressorMetoprolol Tartrate14$1,539
Rosuvastatin Calcium58$1,487
Carvedilol112$1,172
Amlodipine Besylate119$1,079
Hydralazine Hcl53$1,055

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$231$72,96145 claims
AstraZenecaFarxiga$48$19,81212 claims
Johnson & JohnsonXarelto$49$17,86211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Evergreen Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →